Masaki Matsushita Selected Research

Achondroplasia

1/2021	Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish.
1/2020	Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
1/2020	Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: A case report.
12/2017	Activated FGFR3 promotes bone formation via accelerating endochondral ossification in mouse model of distraction osteogenesis.
1/2017	Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
1/2017	Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
8/2016	Low bone mineral density in achondroplasia and hypochondroplasia.
2/2015	Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
1/2013	Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masaki Matsushita Research Topics

Disease

9	Achondroplasia 01/2021 - 01/2013
5	Motion Sickness (Airsickness) 12/2022 - 01/2013
3	Legg-Calve-Perthes Disease (Perthes Disease) 05/2022 - 09/2013
3	Congenital Abnormalities (Deformity) 07/2020 - 11/2013
3	Pathologic Constriction (Stenosis) 01/2017 - 08/2003
3	Neoplasm Metastasis (Metastasis) 11/2006 - 10/2003
2	Necrosis 05/2022 - 10/2004
2	Hypophosphatasia 01/2021 - 03/2014
2	Slipped Capital Femoral Epiphyses 05/2017 - 11/2013
2	Cleidocranial Dysplasia (Cleidocranial Dysostosis) 01/2016 - 01/2014
2	Heterotopic Ossification (Ectopic Ossification) 10/2013 - 01/2013
2	Hepatocellular Carcinoma (Hepatoma) 03/2008 - 10/2004
1	Body Weight (Weight, Body) 12/2022
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 12/2022
1	Inflammation (Inflammations) 03/2022
1	Cataract (Cataracts) 01/2021
1	Retinal Detachment (Retinal Detachments) 01/2021
1	Osteoarthritis 01/2021
1	Infections 07/2020
1	Neoplasms (Cancer) 07/2020
1	Pain (Aches) 07/2020
1	Wounds and Injuries (Trauma) 07/2020
1	Musculoskeletal Pain 07/2020
1	Contracture 11/2018
1	Ischiopatellar dysplasia 01/2018
1	Localized Scleroderma (Morphea) 01/2018
1	Ectromelia (Phocomelia) 05/2016
1	Postoperative Hemorrhage 11/2013
1	Myositis Ossificans (Fibrodysplasia Ossificans Progressiva) 10/2013
1	Developmental Dysplasia of the Hip 09/2013
1	Thanatophoric Dysplasia (Dwarfism, Thanatophoric) 01/2013
1	Chondrosarcoma 01/2013
1	Systemic Scleroderma (Systemic Sclerosis) 08/2008
1	Disease Progression 11/2006
1	Edema (Dropsy) 10/2004
1	Obstructive Jaundice (Cholestatic Jaundice) 10/2004
1	Jaundice (Icterus) 10/2004
1	Genetic Predisposition to Disease (Genetic Predisposition) 05/2004
1	Endometriosis 05/2004

Drug/Important Bio-Agent (IBA)

9	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 01/2021 - 01/2013
7	Meclizine (Meclozine)FDA LinkGeneric 12/2022 - 01/2013
5	Pharmaceutical PreparationsIBA 12/2022 - 01/2013
2	Histamine (Histamine Dihydrochloride)FDA Link 12/2022 - 01/2013
2	Alkaline PhosphataseIBA 01/2021 - 03/2014
2	Nonprescription Drugs (Patent Medicines)IBA 01/2017 - 02/2015
2	Shape Memory AlloysIBA 11/2006 - 12/2004
1	Nonsense Codon (Nonsense Mutation)IBA 12/2022
1	DystrophinIBA 12/2022
1	Indicators and Reagents (Reagents)IBA 03/2022
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2021
1	asfotase alfaIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Alanine (L-Alanine)FDA Link 01/2016
1	phosphorylethanolamine (phosphoethanolamine)IBA 03/2014
1	Transcription Factors (Transcription Factor)IBA 01/2014
1	perhexiline maleateIBA 10/2013
1	PerhexilineIBA 01/2013
1	FendilineIBA 01/2013
1	Interleukin-10 (Interleukin 10)IBA 08/2008
1	Interleukin-10 ReceptorsIBA 08/2008
1	Fluorouracil (Carac)FDA LinkGeneric 12/2004
1	Coloring Agents (Dyes)IBA 10/2004
1	NAD (NADH)IBA 10/2004
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 05/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2004
1	Type II Tumor Necrosis Factor ReceptorsIBA 05/2004

Therapy/Procedure

5	Osteotomy 05/2022 - 11/2013
4	Catheters 11/2006 - 10/2003
3	External Fixators 07/2020 - 11/2013
3	Therapeutics 09/2013 - 03/2008
3	Drug Therapy (Chemotherapy) 11/2006 - 10/2003
2	Operative Time 07/2020 - 11/2013
2	Bone Lengthening 01/2018 - 05/2016
2	Traction 05/2017 - 09/2013
1	Arthroplasty 01/2021
1	Braces 11/2020
1	Aftercare (After-Treatment) 07/2020
1	Transplantation 07/2020
1	Hematopoietic Stem Cell Transplantation 07/2020
1	Orthotic Devices (Orthosis) 11/2018
1	Radiofrequency Ablation 03/2008
1	Indwelling Catheters (Indwelling Catheter) 12/2004
1	Patient Discharge 10/2004
1	Stents 10/2004
1	Laparotomy 08/2003
1	Laparoscopic Cholecystectomy 08/2003